David JD - Alkermes Plc Chief VP

ALKS Stock  USD 27.70  0.21  0.75%   

VP

David JD is Chief VP of Alkermes Plc
Age 52
Address Connaught House, Dublin, Ireland, D04 C5Y6
Phone353 1 772 8000
Webhttps://www.alkermes.com

Alkermes Plc Management Efficiency

The company has return on total asset (ROA) of 0.0898 % which means that it generated a profit of $0.0898 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2923 %, meaning that it created $0.2923 on every $100 dollars invested by stockholders. Alkermes Plc's management efficiency ratios could be used to measure how well Alkermes Plc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024. Return On Capital Employed is likely to gain to 0.27 in 2024. At this time, Alkermes Plc's Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 12.1 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.
Alkermes Plc currently holds 372.19 M in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Alkermes Plc has a current ratio of 2.33, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alkermes Plc's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 12 records

VP Age

MPH MDIronwood Pharmaceuticals
N/A
Anthony CPAPhibro Animal Health
55
William JDPrestige Brand Holdings
59
Paul CoxDynavax Technologies
N/A
Michael JDIntracellular Th
51
Eric FringsDynavax Technologies
N/A
MBA MSIronwood Pharmaceuticals
N/A
Judith WeinsteinPhibro Animal Health
55
Shirley JDCollegium Pharmaceutical
40
Meredith JDANI Pharmaceuticals
50
Mona DesaiPhibro Animal Health
N/A
Meredith CookANI Pharmaceuticals
50
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Alkermes Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2211 people. Alkermes Plc (ALKS) is traded on NASDAQ Exchange in USA. It is located in Connaught House, Dublin, Ireland, D04 C5Y6 and employs 2,100 people. Alkermes Plc is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Alkermes Plc Leadership Team

Elected by the shareholders, the Alkermes Plc's board of directors comprises two types of representatives: Alkermes Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alkermes. The board's role is to monitor Alkermes Plc's management team and ensure that shareholders' interests are well served. Alkermes Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alkermes Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Peter Norman, Senior Relations
David Gaffin, Senior Vice President Chief Legal Officer
Richard Pops, Chairman and CEO
Iain Brown, Chief Accounting Officer
Blair Jackson, Executive Officer
Declan OConnor, Health Environment
Samuel Parisi, Interim Finance
Stephen Schiavo, Senior Resources
Michael Landine, Senior Vice President - Corporate Development
Thomas Harvey, Chief IT
Craig MD, Executive Officer
Floyd MD, Founder
David JD, Chief VP
Sandra Coombs, Senior Relations

Alkermes Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alkermes Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Alkermes Stock Analysis

When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.